A documentary focusing on the area of psychedelic drugs as a potential treatment for mental-health issues. The documentary features several individuals who share their experiences and feelings regarding psychedelics.
In the documentary, area war hero Patrick Moulden noted that he is taking a chance on psychedelics in a bid to help manage his mental distress. Russell Peters, a comedian who recently joined a psychedelic firm based in Canada, stated that there were a lot of individuals who suffered from depression, adding that he was one of them. World-renowned addiction specialist Dr. Evan Wood says that psychedelics had enough potential to be the equivalent of a cancer cure in the mental-health space.
However, many are still concerned regarding the efficacy of psychedelics. Moulden, who was awarded the Medal of Bravery for his work in Afghanistan, is on a mission to find out just how effective they are. By sharing his journey in the documentary, titled “The Psychedelic Frontier,” Moulden is hoping to show how psychedelics help manage mental-health conditions. Moulden explained that what he had seen in Afghanistan impacted him in a way that’s hard to imagine, adding that the horrors he’d seen still haunt him.
Moulden, who suffers from extreme post-traumatic stress disorder, stated that he’d tried various modern medicines, from pills and sleep medications to antidepressants, to help manage his anxiety. However, nothing worked. He then turned to psychedelics, hoping to manage his mental anguish. The psychedelic Moulden will be using is iboga, a shrub that grows in mainly in Africa.
Mark Howard, an experienced practitioner, explained that iboga possesses physical abilities that could help individuals get rid of toxins from their bodies. The psychedelic plant has the ability to clean up an individual’s spirit as well, Howard added, while providing them with the opportunity to look deep into themselves and look through their experiences to find out what’s affecting them.
Dennis McKenna, an ethno pharmacologist, explained that the move to psychedelics by individuals seeking for help was happening because conventional mental health treatments were not always effective for every individual. McKenna explained that studies on psychedelics had shown that they were both effective and safe in treating mental-health conditions.
However, the clinical trials on various psychedelics have still not been concluded. Additionally, psychedelic drugs such as psilocybin mushrooms are not legal to prescribe in Canada.
The documentary will feature Moulden who, under the care of professionals, will ingest the psychedelic drug in an ancient ceremony. In addition to this, various scientists in Canada who are studying other psychedelic such as psilocybin mushrooms are included in the documentary.
Also in the Canadian psychedelics space, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) is well placed, due to its expertise in the cannabis extracts business, to ease into pole position in terms of rapidly developing and then commercializing functional mushroom plus therapeutic psychedelic products.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
